Patti, Giuseppe http://orcid.org/0000-0002-5404-3968
,
Lio, Veronica
Cavallari, Ilaria
Gragnano, Felice
Riva, Letizia
Calabrò, Paolo
Di Pasquale, Giuseppe
Pengo, Vittorio
Rubboli, Andrea
Funding for this research was provided by:
Università degli Studi del Piemonte Orientale Amedeo Avogrado
Article History
Accepted: 1 October 2020
First Online: 3 November 2020
Declarations
:
: Giuseppe Patti, Veronica Lio, Ilaria Cavallari, Felice Gragnano, Letizia Riva, Paolo Calabrò, Giuseppe Di Pasquale, Vittorio Pengo, and Andrea Rubboli declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
: Open access funding provided by Università degli Studi del Piemonte Orientale Amedeo Avogrado within the CRUI-CARE Agreement. None.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: GP: Lecture fee/consultant/advisory board for Amgen, Sanofi, Bayer, Boehringer Ingelheim, BMS-Pfizer, Daiichi Sankyo, Astra Zeneca, Sigma-Tau, Malesci, PIAM, and MSD. VL: None. IC: Lecture fee for Boehringer Ingelheim and BMS-Pfizer. FG: None. LR: Lecture fee/consultant/advisory board for Boehringer Ingelheim, Bayer, and Daiichi Sankyo. PC: Lecture fee/consultant/advisory board for Amgen, Sanofi, Bayer, Boehringer Ingelheim, BMS-Pfizer, Daiichi Sankyo, Astra Zeneca, and MSD. GDP: Lecture fee/consultant/advisory board for Boehringer Ingelheim, BMS-Pfizer, Bayer, and Daiichi Sankyo. VP: Lecture fee/consultant/advisory board for Bayer, Daiichi Sankyo, and Werfen Group. AR: Lecture fee/consultant/advisory board for Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer-BMS.